{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:54:05Z","timestamp":1785873245591,"version":"3.56.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Tehran University of Medical Sciences","award":["27749"],"award-info":[{"award-number":["27749"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.psychres.2018.02.012","type":"journal-article","created":{"date-parts":[[2018,2,3]],"date-time":"2018-02-03T09:05:45Z","timestamp":1517648745000},"page":"94-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial"],"prefix":"10.1016","volume":"262","author":[{"given":"Alireza","family":"Ghajar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Reza","family":"Khoaie-Ardakani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahara","family":"Shahmoradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir-Reza","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Afarideh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Reza","family":"Shalbafan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Ghazizadeh-Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahin","family":"Akhondzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.psychres.2018.02.012_bib1","first-page":"295","article-title":"The 5-HT hypothesis of schizophrenia","volume":"4","author":"Akhondzadeh","year":"2001","journal-title":"IDrugs"},{"issue":"5","key":"10.1016\/j.psychres.2018.02.012_bib2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2710.2000.00295.x","article-title":"Double-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawal","volume":"25","author":"Akhondzadeh","year":"2000","journal-title":"J. Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.psychres.2018.02.012_bib3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.schres.2006.11.016","article-title":"Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial","volume":"90","author":"Akhondzadeh","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2018.02.012_bib4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.psychres.2017.05.029","article-title":"Efficacy and safety of celecoxib monotherapy for mild to moderate depression in patients with colorectal cancer: a randomized double-blind, placebo controlled trial","volume":"255","author":"Alamdarsaravi","year":"2017","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.psychres.2018.02.012_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1586\/17512433.2016.1095086","article-title":"Anti-inflammatory strategies in the treatment of schizophrenia","volume":"9","author":"Andrade","year":"2015","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.psychres.2018.02.012_bib6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.coph.2014.12.004","article-title":"The NMDA receptor \u2018glycine modulatory site\u2019in schizophrenia: d-serine, glycine, and beyond","volume":"20","author":"Balu","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"issue":"13","key":"10.1016\/j.psychres.2018.02.012_bib7","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s00213-016-4318-6","article-title":"Targeting glutamate to treat schizophrenia: lessons from recent clinical studies","volume":"233","author":"Beck","year":"2016","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.psychres.2018.02.012_bib8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","article-title":"N-acetyl cysteine as a glutathione precursor for schizophrenia\u2014a double-blind, randomized, placebo-controlled trial","volume":"64","author":"Berk","year":"2008","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2018.02.012_bib9","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/schbul\/sbl057","article-title":"Persistent negative symptoms in schizophrenia: an overview","volume":"33","author":"Buchanan","year":"2007","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.psychres.2018.02.012_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.schres.2012.10.001","article-title":"A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia","volume":"142","author":"Chengappa","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2018.02.012_bib11","unstructured":"Chouinard, G., RossChouinard, A., Annable, L., Jones, B., 1980. Extrapyramidal symptom rating-scale. Paper presented at the Canadian Journal of Neurological Sciences."},{"key":"10.1016\/j.psychres.2018.02.012_bib12","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2147\/NDT.S43404","article-title":"Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options","volume":"10","author":"Chue","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"1","key":"10.1016\/j.psychres.2018.02.012_bib13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.schres.2014.12.026","article-title":"The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia","volume":"167","author":"Cohen","year":"2015","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.psychres.2018.02.012_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00213-003-1709-2","article-title":"The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia","volume":"174","author":"Coyle","year":"2004","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1016\/j.psychres.2018.02.012_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4088\/JCP.08m04935gry","article-title":"Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine","volume":"70","author":"De Lucena","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2018.02.012_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0920-9964(01)00220-1","article-title":"D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia","volume":"56","author":"Evins","year":"2002","journal-title":"Schizophr. Res."},{"issue":"11","key":"10.1016\/j.psychres.2018.02.012_bib17","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/archpsyc.1991.01810350018003","article-title":"Natural history of schizophrenia subtypes: ii. Positive and negative symptoms and long-term course","volume":"48","author":"Fenton","year":"1991","journal-title":"Arch. Gen. Psychiatry"},{"issue":"12","key":"10.1016\/j.psychres.2018.02.012_bib18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.molmed.2011.08.004","article-title":"Targeting glutamate synapses in schizophrenia","volume":"17","author":"Field","year":"2011","journal-title":"Trends Mol. Med."},{"issue":"04","key":"10.1016\/j.psychres.2018.02.012_bib19","first-page":"152","article-title":"Crocus sativus L. versus Citalopram in the treatment of major depressive disorder with anxious distress: a double-blind, controlled clinical trial","volume":"50","author":"Ghajar","year":"2016","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2018.02.012_bib20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archpsyc.56.1.21","article-title":"A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia","volume":"56","author":"Goff","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2018.02.012_bib21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.neulet.2007.05.048","article-title":"Carnosine ameliorates morphine-induced conditioned place preference in rats","volume":"422","author":"Gong","year":"2007","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.psychres.2018.02.012_bib22","article-title":"l-Carnosine as an adjunctive therapy to risperidone in children with autistic disorder: aa randomized, double-blind, placebo-controlled trial","author":"Hajizadeh-Zaker","year":"2017","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2018.02.012_bib23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2018.02.012_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.psychres.2010.02.014","article-title":"Plasma alanine levels increase in patients with schizophrenia as their clinical symptoms improve\u2014Results from the Juntendo University Schizophrenia Projects (JUSP)","volume":"177","author":"Hatano","year":"2010","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.psychres.2018.02.012_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0920-9964(03)00129-4","article-title":"Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis","volume":"66","author":"Heresco-Levy","year":"2004","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.psychres.2018.02.012_bib26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.mam.2011.10.004","article-title":"Energy metabolism, proteotoxic stress and age-related dysfunction\u2013Protection by carnosine","volume":"32","author":"Hipkiss","year":"2011","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.psychres.2018.02.012_bib27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev.pharmtox.010909.105851","article-title":"Schizophrenia: treatment targets beyond monoamine systems","volume":"51","author":"Ibrahim","year":"2011","journal-title":"Annu Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.psychres.2018.02.012_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2016.05.076","article-title":"Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: a double-blind, randomized, controlled trial","volume":"204","author":"Jafarinia","year":"2016","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.psychres.2018.02.012_bib29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S2215-0366(15)00098-X","article-title":"D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial","volume":"2","author":"Kantrowitz","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.psychres.2018.02.012_bib30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jpsychires.2017.06.011","article-title":"Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: a randomized double-blind placebo-controlled clinical trial","volume":"94","author":"Kashani","year":"2017","journal-title":"J. Psychiatr. Res."},{"issue":"46","key":"10.1016\/j.psychres.2018.02.012_bib31","doi-asserted-by":"crossref","first-page":"19240","DOI":"10.1021\/ja309273n","article-title":"Computational design of effective, bioinspired HOCl antioxidants: the role of intramolecular Cl + and H + shifts","volume":"134","author":"Karton","year":"2012","journal-title":"J. Am. Chem. Soc."},{"issue":"2","key":"10.1016\/j.psychres.2018.02.012_bib32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.psychres.2018.02.012_bib33","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr. Bull."},{"issue":"3\u20134","key":"10.1016\/j.psychres.2018.02.012_bib34","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00213-003-1582-z","article-title":"NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development","volume":"169","author":"Krystal","year":"2003","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.psychres.2018.02.012_bib35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00726-011-1135-4","article-title":"Carnosine protects neurons against oxidative stress and modulates the time profile of MAPK cascade signaling","volume":"43","author":"Kulebyakin","year":"2012","journal-title":"Amino Acids"},{"issue":"2","key":"10.1016\/j.psychres.2018.02.012_bib36","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4306\/pi.2012.9.2.166","article-title":"Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study","volume":"9","author":"Lee","year":"2012","journal-title":"Psychiatry Investig."},{"issue":"5","key":"10.1016\/j.psychres.2018.02.012_bib37","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/npp.2008.200","article-title":"A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia","volume":"34","author":"Lieberman","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.psychres.2018.02.012_bib38","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.jpsychires.2013.09.002","article-title":"Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: an updated meta-analysis of randomized placebo-controlled trials","volume":"47","author":"Matsuda","year":"2013","journal-title":"J. Psychiatr. Res."},{"issue":"7","key":"10.1016\/j.psychres.2018.02.012_bib39","first-page":"817","article-title":"Applicability of zinc complex of L-carnosine for medical use","volume":"65","author":"Matsukura","year":"2000","journal-title":"Biochemistry (Mosc)."},{"issue":"4","key":"10.1016\/j.psychres.2018.02.012_bib40","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0026-895X(25)09633-6","article-title":"Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytes","volume":"36","author":"McBain","year":"1989","journal-title":"Mol. Pharmacol."},{"issue":"7","key":"10.1016\/j.psychres.2018.02.012_bib41","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1523\/JNEUROSCI.22-07-02718.2002","article-title":"Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia","volume":"22","author":"Middleton","year":"2002","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.psychres.2018.02.012_bib42","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.euroneuro.2014.03.008","article-title":"Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment","volume":"24","author":"Millan","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2018.02.012_bib43","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.psychres.2018.02.012_bib44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.schres.2006.07.002","article-title":"Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review","volume":"88","author":"Murphy","year":"2006","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.psychres.2018.02.012_bib45","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00213-012-2729-6","article-title":"Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial","volume":"223","author":"Modabbernia","year":"2012","journal-title":"Psychopharmacol. (Berl.)."},{"issue":"3","key":"10.1016\/j.psychres.2018.02.012_bib46","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","article-title":"Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism","volume":"128","author":"Neill","year":"2010","journal-title":"Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.psychres.2018.02.012_bib47","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1055\/s-0042-101557","article-title":"Duloxetine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study","volume":"49","author":"Nikbakhat","year":"2016","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2018.02.012_bib48","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00213-013-3064-2","article-title":"A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia","volume":"228","author":"Noroozian","year":"2013","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.psychres.2018.02.012_bib49","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1046\/j.1365-2710.1999.00238.x","article-title":"Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia","volume":"24","author":"Noorbala","year":"1999","journal-title":"J. Clin. Pharm. Ther."},{"issue":"11","key":"10.1016\/j.psychres.2018.02.012_bib50","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.euroneuro.2008.06.005","article-title":"Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology","volume":"18","author":"Paz","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2018.02.012_bib51","doi-asserted-by":"crossref","first-page":"2939087","DOI":"10.1155\/2016\/2939087","article-title":"Use of carnosine for oxidative stress reduction in different pathologies","volume":"2016","author":"Prokopieva","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"3","key":"10.1016\/j.psychres.2018.02.012_bib52","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/JCP.0b013e31828b50a7","article-title":"Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study","volume":"33","author":"Rezaei","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.psychres.2018.02.012_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2583","article-title":"Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: randomized, double-blind, placebo-controlled study","volume":"32","author":"Rezaei","year":"2017","journal-title":"Hum. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2018.02.012_bib54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00001756-199310000-00001","article-title":"Presynaptic colocalization of carnosine and glutamate in olfactory neurones","volume":"5","author":"Sasso\u00e8-Pognetto","year":"1993","journal-title":"NeuroReport"},{"key":"10.1016\/j.psychres.2018.02.012_bib55","first-page":"727","article-title":"Carnosine protects against permanent cerebral ischemia in histidine decarboxylase knockout mice by reducing glutamate excitotoxicity","volume":"48","author":"Shen","year":"2010"},{"issue":"5","key":"10.1016\/j.psychres.2018.02.012_bib56","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.bcp.2006.11.007","article-title":"Carnosine protects against NMDA-induced neurotoxicity in differentiated rat PC12 cells through carnosine-histidine-histamine pathway and H 1\/H 3 receptors","volume":"73","author":"Shen","year":"2007","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.psychres.2018.02.012_bib57","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/YIC.0000000000000159","article-title":"Simvastatin adjunct therapy for negative symptoms of schizophrenia: a randomized double-blind placebo-controlled trial","volume":"32","author":"Tajik-Esmaeeli","year":"2017","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.psychres.2018.02.012_bib58","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.biopsych.2005.06.032","article-title":"D-alanine added to antipsychotics for the treatment of schizophrenia","volume":"59","author":"Tsai","year":"2006","journal-title":"Biol. Psychiatry"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178117318012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178117318012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T14:18:14Z","timestamp":1751293094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178117318012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":58,"alternative-id":["S0165178117318012"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2018.02.012","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2018.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}